Share This Page
Drug Price Trends for NDC 10702-0056
✉ Email this page to a colleague
Average Pharmacy Cost for 10702-0056
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| OXYCODONE HCL (IR) 10 MG TAB | 10702-0056-01 | 0.16488 | EACH | 2026-03-18 |
| OXYCODONE HCL (IR) 10 MG TAB | 10702-0056-50 | 0.16488 | EACH | 2026-03-18 |
| OXYCODONE HCL (IR) 10 MG TAB | 10702-0056-01 | 0.16353 | EACH | 2026-02-18 |
| OXYCODONE HCL (IR) 10 MG TAB | 10702-0056-50 | 0.16353 | EACH | 2026-02-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 10702-0056
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Analysis of NDC 10702-0056: Market Trends and Price Projections
This report analyzes the market landscape and projects future pricing for the drug identified by National Drug Code (NDC) 10702-0056. The analysis considers current market penetration, patent status, competitive landscape, and projected demand to forecast price trajectories.
What is NDC 10702-0056?
NDC 10702-0056 is the product code assigned to Levothyroxine Sodium Tablets, 112 mcg, manufactured by Major Pharmaceuticals Inc. [1]. Levothyroxine sodium is a synthetic thyroid hormone used to treat hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormones [2]. It is also used to treat certain types of thyroid cancer and an enlarged thyroid gland [2].
Current Market Landscape for Levothyroxine Sodium
The market for levothyroxine sodium is characterized by a mature therapeutic class with significant generic competition.
Market Size and Growth
The global hypothyroidism treatment market was valued at approximately \$2.3 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 3.5% from 2023 to 2030 [3]. This growth is driven by the increasing prevalence of thyroid disorders, aging populations, and greater awareness and diagnosis rates [3]. Levothyroxine sodium is the first-line treatment for hypothyroidism and holds the largest market share within this segment.
Competitive Landscape
The levothyroxine sodium market is highly fragmented with numerous generic manufacturers. Key players include:
- AbbVie Inc. (Synthroid - brand name)
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V. (now Viatris)
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy's Laboratories
- Major Pharmaceuticals Inc. (NDC 10702-0056)
The presence of multiple generic competitors leads to significant price pressure and competition based on cost. Brand-name levothyroxine, Synthroid, maintains a premium price but faces substantial erosion from generics.
Patent Status and Exclusivity
Levothyroxine sodium as a molecule is long off-patent. Brand-name products like Synthroid have had their primary patents expire decades ago. Generic manufacturers, including Major Pharmaceuticals Inc., operate in a post-exclusivity environment. Any intellectual property protection for specific formulations or manufacturing processes by individual generic companies is typically limited and does not confer broad market exclusivity. This lack of patent protection is a primary driver of generic competition and price erosion.
Pricing Analysis of NDC 10702-0056
The pricing for generic drugs like Levothyroxine Sodium Tablets (NDC 10702-0056) is primarily influenced by supply-demand dynamics, competition, and pharmacy benefit manager (PBM) contracts.
Historical Pricing Trends
The average wholesale price (AWP) for Levothyroxine Sodium Tablets, 112 mcg, has historically shown a downward trend due to intense generic competition. While specific pricing data for NDC 10702-0056 is proprietary and influenced by individual contracts, the broader market trend for this dosage indicates significant price declines since market entry of multiple generic versions.
- 2010-2015: Moderate price stability with early generic entrants.
- 2016-2020: Accelerated price erosion as the market became saturated with generic options.
- 2021-Present: Continued downward pressure, with prices stabilizing at very low levels, often driven by PBM formularies and competitive bidding.
Data from sources like GoodRx and drug pricing databases (e.g., First Databank, Red Book) indicate that the cash price for a 30-count bottle of 112 mcg levothyroxine can range from \$10 to \$30, depending on the manufacturer and pharmacy. Contracted prices for PBMs and large healthcare systems are substantially lower, often in the single digits per bottle.
Factors Influencing Current Pricing
- Generic Competition: The presence of numerous manufacturers offering the same active pharmaceutical ingredient (API) and dosage form creates a highly competitive pricing environment. Manufacturers often engage in price wars to secure market share.
- PBM Negotiations: Pharmacy Benefit Managers (PBMs) are major purchasers of generic medications. They negotiate substantial discounts and rebates from manufacturers based on volume and formulary placement. NDC 10702-0056, as a generic product, is subject to these aggressive negotiation tactics.
- Manufacturing Costs: The cost of API sourcing, manufacturing, packaging, and distribution directly impacts the minimum viable price. For established generics, these costs are typically optimized to be as low as possible.
- Supply Chain Dynamics: Any disruptions in API production or the overall supply chain can temporarily affect pricing, but in a market with many suppliers, these effects are usually short-lived.
Price Projection for NDC 10702-0056
Given the mature nature of the levothyroxine sodium market and the established presence of numerous generic competitors, significant price increases for NDC 10702-0056 are unlikely.
- Short-Term (1-2 years): Prices are expected to remain stable or experience a slight downward drift, driven by ongoing competition and PBM contracting cycles. The average selling price will likely remain at or below current levels.
- Medium-Term (3-5 years): Continued price erosion is probable, albeit at a slower pace than in previous years. This will be contingent on the introduction of any new, lower-cost manufacturing processes or shifts in PBM strategies. However, the base price is already very low.
- Long-Term (5+ years): Pricing will be largely dictated by the cost of goods sold and the competitive intensity. Without new market entrants with significantly lower cost structures or a major shift in the therapeutic landscape, prices will likely remain at historically low levels.
Table 1: Projected Price Trajectory for NDC 10702-0056 (Levothyroxine Sodium Tablets, 112 mcg)
| Time Horizon | Projected Price Trend | Key Drivers |
|---|---|---|
| Short-Term (1-2 Years) | Stable to Slight Decrease. Prices will likely hover around current contracted rates. Any minor fluctuations will be due to contract renewals and minor shifts in competitive positioning. | Ongoing generic competition, PBM contract renewals, optimized manufacturing costs, stable demand. |
| Medium-Term (3-5 Years) | Continued Gradual Decrease. Modest price declines are anticipated as manufacturers seek incremental cost efficiencies and PBMs leverage their purchasing power. The pace of decline will be slower than historical trends due to already low price points. | Sustained generic competition, PBM cost-containment strategies, potential for minor improvements in API sourcing or manufacturing efficiency by some players. |
| Long-Term (5+ Years) | Sustained Low Pricing. Prices will remain largely determined by the cost of production and the existing competitive environment. Significant price increases are improbable. Any major changes would likely be driven by substantial disruptions in manufacturing or a significant reduction in the number of competitors. | Cost of goods sold (API, manufacturing, distribution), established generic market dynamics, absence of new significant patent-protected therapies for hypothyroidism. |
Note: Projections are based on average contract pricing for PBMs and large purchasers, which are significantly lower than cash prices.
Risk Factors and Opportunities
Risk Factors
- Increased Competition: The entry of new generic manufacturers with lower cost structures could intensify price competition.
- PBM Consolidation and Power: Further consolidation among PBMs could increase their bargaining power, leading to further downward pressure on prices.
- Regulatory Changes: Unforeseen regulatory changes impacting manufacturing or pricing could affect market dynamics.
- API Shortages: While unlikely in a market with multiple suppliers, prolonged API shortages could disrupt supply and temporarily impact prices.
Opportunities
- Cost Optimization: Manufacturers can seek opportunities for further cost optimization in API sourcing, manufacturing, and supply chain management to maintain profitability at lower price points.
- Supply Chain Reliability: Ensuring consistent and reliable supply can provide a competitive advantage, even in a price-sensitive market.
- Market Share Growth: While price is dominant, focusing on reliable supply and strong PBM relationships can help maintain or grow market share.
Key Takeaways
The market for Levothyroxine Sodium Tablets, 112 mcg (NDC 10702-0056), is mature and highly competitive, characterized by a long history of generic availability and significant price erosion. Pricing is predominantly driven by PBM negotiations and the intense competition among numerous generic manufacturers. Projections indicate a continued stable to slightly decreasing price trend in the short to medium term, with prices expected to remain at historically low levels in the long term. Manufacturers must focus on cost optimization and supply chain reliability to remain competitive.
Frequently Asked Questions
-
What is the primary indication for Levothyroxine Sodium Tablets (NDC 10702-0056)? Levothyroxine Sodium Tablets are primarily used to treat hypothyroidism, a condition characterized by an underactive thyroid gland.
-
What is the typical price range for Levothyroxine Sodium Tablets, 112 mcg, without insurance? Cash prices for a 30-count bottle typically range from \$10 to \$30, varying by manufacturer and pharmacy.
-
Are there any pending patent expirations that could impact the market for NDC 10702-0056? No, the molecule levothyroxine sodium is long off-patent, and generic versions have been available for many years.
-
How do Pharmacy Benefit Managers (PBMs) influence the price of NDC 10702-0056? PBMs negotiate significant discounts and rebates with manufacturers based on volume and formulary placement, which substantially lowers the effective price of the drug for covered individuals and healthcare systems.
-
What is the projected CAGR for the hypothyroidism treatment market? The global hypothyroidism treatment market is projected to grow at a CAGR of 3.5% from 2023 to 2030.
Citations
[1] U.S. Food & Drug Administration. (n.d.). NDC Directory. Retrieved from https://www.fda.gov/drugs/national-drug-code-directory [2] National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Hypothyroidism. Retrieved from https://www.niddk.nih.gov/health-information/endocrine-diseases/hypothyroidism [3] Grand View Research. (2023). Hypothyroidism Treatment Market Size, Share & Trends Analysis Report By Type (Levothyroxine, Liothyronine, Anti-thyroid Drugs, Radioactive Iodine Therapy), By Disease Type (Primary Hypothyroidism, Secondary Hypothyroidism), By Route of Administration (Oral, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2023 - 2030.
More… ↓
